Cited by 520Diabetes and associated disordersDiabetes Management and ResearchPancreatic function and diabetes

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes

Open access

Ludvigsson, Johnny, Faresjö, Maria, Hjorth, Maria, Axelsson, Stina, Chéramy, Mikael, Pihl, Mikael, Vaarala, Outi, Forsander, Gun, Ivarsson, Sten, Johansson, Calle, Lindh, Agne, Nilsson, Nils-Östen, Åman, Jan, Örtqvist, Eva, Zerhouni, Peter, Casas, Rosaura·2008·New England Journal of Medicine

DOI 10.1056/nejmoa0804328

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The 65-kD isoform of glutamic acid decarboxylase (GAD) is a major autoantigen in patients with type 1 diabetes mellitus. This trial assessed the ability of alum-formulated GAD (GAD-alum) to reverse recent-onset type 1 diabetes in patients 10 to 18 years of age. METHODS: We randomly assigned 70 patients with type 1 diabetes who had fasting C-peptide levels above 0.1 nmol per liter (0.3 ng per milliliter) and GAD autoantibodies, recruited within 18 months after receiving the diagnosis of diabetes, to receive subcutaneous injections of 20 microg of GAD-alum (35 patients) or placebo (alum alone, 35 patients) on study days 1 and 30. At day 1 and months 3, 9, 15, 21, and 30, patients underwent a mixed-meal tolerance test to stimulate residual insulin secretion (measured as the C-peptide level). The effect of GAD-alum on the immune system was also studied. RESULTS: Insulin secretion gradually decreased in both study groups. The study treatment had no significant effect on change in fasting C-peptide level after 15 months (the primary end point). Fasting C-peptide levels declined from baseline levels significantly less over 30 months in the GAD-alum group than in the placebo group (-0.21 vs. -0.27 nmol per liter [-0.62 vs. -0.81 ng per milliliter], P=0.045), as did stimulated secretion measured as the area under the curve (-0.72 vs. -1.02 nmol per liter per 2 hours [-2.20 vs. -3.08 ng per milliliter per 2 hours], P=0.04). No protective effect was seen in patients treated 6 months or more after receiving the diagnosis. Adverse events appeared to be mild and similar in frequency between the two groups. The GAD-alum treatment induced a GAD-specific immune response. CONCLUSIONS: GAD-alum may contribute to the preservation of residual insulin secretion in patients with recent-onset type 1 diabetes, although it did not change the insulin requirement. (ClinicalTrials.gov number, NCT00435981.)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa0804328

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
Type 1 diabetes: new perspectives on disease pathogenesis and treatment
Atkinson, M. A., & Eisenbarth, G. S. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05415-0 · Cited by 1,491
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
β-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control and Complications Trial
Steffes, M. W., Sibley, S., Jackson, M., & Thomas, W. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.832 · Cited by 695
A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes
Herold, K. C., Gitelman, S. E., Masharani, U. B., Hagopian, W., Bisikirska, B. C., DONALDSON, D. L., Rother, K. I., Diamond, B. E., Harlan, D. M., & Bluestone, J. A. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1763 · Cited by 641
Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins
Bækkeskov, S., Nielsen, J. H., Marner, B., Bilde, T., Ludvigsson, J., & Lernmark, Å. (1982) · Nature · doi:10.1038/298167a0 · Cited by 530
Self-citation
β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial
Raz, I., Elias, D., Avron, A., Tamir, M., Metzger, M., & Cohen, I. R. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06801-5 · Cited by 508
Randomisation and baseline comparisons in clinical trials
Altman, D. G., & Doré, C. J. (1990) · The Lancet · doi:10.1016/0140-6736(90)90014-v · Cited by 508
Beneficial effects of intensive therapy of diabetes during adolescence: Outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT)
White, N. H., Cleary, P. A., Dahms, W. T., Goldstein, D. E., Malone, J. K., & Tamborlane, W. V. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.118887 · Cited by 458

Show all 32 references

Research works printed but not linked: 3

Dupre J, 1988, Diabetes Care, 11, 37
Eisenbarth GS, 1985, Diabetes Res, 2, 271
Daneman D, 1987, Clin Invest Med, 10, 484

Sorted by citations

Type 1 diabetes
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60591-7 · Cited by 2,931
Type 1 diabetes mellitus
Katsarou, A., Gudbjörnsdottir, S., Rawshani, A., Dabelea, D., Bonifacio, E., Anderson, B. J., Jacobsen, L. M., Schatz, D. A., & Lernmark, Å. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.16 · Cited by 1,475
Genetics, pathogenesis and clinical interventions in type 1 diabetes
Bluestone, J. A., Herold, K., & Eisenbarth, G. (2010) · Nature · doi:10.1038/nature08933 · Cited by 1,265
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies
Van Belle, T. L., Coppieters, K. T., & Von Herrath, M. G. (2011) · Physiological Reviews · doi:10.1152/physrev.00003.2010 · Cited by 1,022
Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?)
Roep, B. O., Thomaidou, S., van Tienhoven, R., & Zaldumbide, A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00443-4 · Cited by 675
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial
Orban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60886-6 · Cited by 612
Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial
Sherry, N., Hagopian, W., Ludvigsson, J., Jain, S. M., Wahlen, J., Ferry, R. J., Bode, B., Aronoff, S., Holland, C., Carlin, D., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60931-8 · Cited by 493
Self-citation
C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus
Couri, C. E. B. (2009) · JAMA · doi:10.1001/jama.2009.470 · Cited by 449
Mechanism of Immunopotentiation and Safety of Aluminum Adjuvants
HogenEsch, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00406 · Cited by 430
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial
Wherrett, D. K., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Marks, J. B., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60895-7 · Cited by 371
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials
Moran, A., Bundy, B. N., BECKER, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Greenbaum, C. J., Herold, K. C., Marks, J. B., Raskin, P., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60023-9 · Cited by 364
Identification of Type 1 Diabetes–Associated DNA Methylation Variable Positions That Precede Disease Diagnosis
Rakyan, V. K., Beyan, H., Down, T. A., Hawa, M. I., Maslau, S., Aden, D., Daunay, A., Busato, F., Mein, C. A., Manfras, B. J., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002300 · Cited by 347
GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus
Ludvigsson, J., Krisky, D., Casas, R., Battelino, T., Castaño, L., Greening, J., Kordonouri, O., Otonkoski, T., Pozzilli, P., Robert, J.-J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107096 · Cited by 340
Self-citation
Clinical Applications of Diabetes Antibody Testing
Bingley, P. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1365 · Cited by 278
Blockade of interleukin 1 in type 1 diabetes mellitus
Mandrup-Poulsen, T. R., Pickersgill, L., & Donath, M. Y. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.271 · Cited by 240
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes
Herold, K. C., Vignali, D. A. A., Cooke, A., & Bluestone, J. A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3422 · Cited by 237
Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes
Hagopian, W., Ferry, R. J., Sherry, N., Carlin, D., Bonvini, E., Johnson, S., Stein, K. E., Koenig, S., Daifotis, A. G., Herold, K. C., et al. (2013) · Diabetes · doi:10.2337/db13-0236 · Cited by 247
Self-citation
Autoimmune polyglandular syndromes
Michels, A. W., & Gottlieb, P. A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.40 · Cited by 235
How Does Type 1 Diabetes Develop?
Atkinson, M. A., Bluestone, J. A., Eisenbarth, G. S., Hebrok, M., Herold, K. C., Accili, D., Pietropaolo, M., Arvan, P. R., Von Herrath, M., Markel, D. S., et al. (2011) · Diabetes · doi:10.2337/db10-1797 · Cited by 232
Antigen-specific therapeutic approaches for autoimmunity
Serra, P., & Santamaría, P. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0015-4 · Cited by 232
The immunology of type 1 diabetes
Herold, K. C., Delong, T., Perdigoto, A. L., Biru, N., Brusko, T. M., & Walker, L. S. K. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-023-00985-4 · Cited by 241
Antigen Targets of Type 1 Diabetes AutoimmunityPreprint
Roep, B. O., & Peakman, M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007781 · Cited by 219
Regulatory T cell dysfunction in type 1 diabetes: what's broken and how can we fix it?
Hull, C. M., Peakman, M., & Tree, T. I. M. (2017) · Diabetologia · doi:10.1007/s00125-017-4377-1 · Cited by 194
Current Advances and Travails in Islet Transplantation
Harlan, D. M., Kenyon, N. S., Korsgren, O., Roep, B. O., & for the Immunology of Diabetes Society (2009) · Diabetes · doi:10.2337/db09-0476 · Cited by 194
Latent Autoimmune Diabetes in Adults
Naik, R. G., Brooks-Worrell, B. M., & Palmer, J. P. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1120 · Cited by 249
Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells
Zhao, Y. L., Jiang, Z., Zhao, T., Ye, M., Hu, C., Yin, Z., Li, H., Zhang, Y., Diao, Y., Li, Y., et al. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-3 · Cited by 189
Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease
Driver, J. P., SERREZE, D. V., & Chen, Y. (2010) · Seminars in Immunopathology · doi:10.1007/s00281-010-0204-1 · Cited by 186
The gut microbiota and Type 1 Diabetes
Gülden, E., Wong, F. S., & Li, W. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.05.013 · Cited by 165
Oral Delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 byLactococcus lactisReverses Diabetes in Recent-Onset NOD Mice
Robert, S., Gysemans, C. A., Takiishi, T., Korf, H., Spagnuolo, I., Sebastiani, G., Huynegem, K. V., Steidler, L., Caluwaerts, S., Demetter, P., et al. (2014) · Diabetes · doi:10.2337/db13-1236 · Cited by 165
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
Herold, K. C., Gitelman, S. E., Willi, S. M., Gottlieb, P. A., Waldron-Lynch, F., Devine, L., Sherr, J. L., Rosenthal, S. M., Adi, S., Jalaludin, M. Y., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2753-4 · Cited by 166
Failure to Preserve β-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New- Onset Type 1 Diabetes
Gottlieb, P. A., Quinlan, S. C., Krause-Steinrauf, H. J., Greenbaum, C. J., Wilson, D. M., Rodriguez, H., Schatz, D., Moran, A., Lachin, J. M., Skyler, J. S., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1349 · Cited by 157
Immunologic endocrine disorders
Michels, A. W., & Eisenbarth, G. S. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.053 · Cited by 153
Effect of Cholecalciferol as Adjunctive Therapy With Insulin on Protective Immunologic Profile and Decline of Residual β-Cell Function in New-Onset Type 1 Diabetes Mellitus
Gabbay, M. A. L., Sato, M. N., Finazzo, C., Duarte, A. J. S., & Dib, S. A. (2012) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpediatrics.2012.164 · Cited by 149
Current Concepts on the Pathogenesis of Type 1 Diabetes—Considerations for Attempts to Prevent and Reverse the Disease
Atkinson, M. A., von Herrath, M., Powers, A. C., & Clare-Salzler, M. J. (2015) · Diabetes Care · doi:10.2337/dc15-0144 · Cited by 150
Autoimmune Markers in Diabetes
Winter, W. E., & Schatz, D. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.148205 · Cited by 147
Immunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going?
Luo, X., Herold, K. C., & Miller, S. D. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.002 · Cited by 138
Effects of exenatide alone and in combination with daclizumab on β-cell function in long-standing type 1 diabetes
Rother, K. I., Spain, L. M., Wesley, R. A., Digon, B. J., Baron, A., Chen, K., Nelson, P., Dosch, H.-M., Palmer, J. P., Brooks-Worrell, B., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0773 · Cited by 133
Immune mechanisms in type 1 diabetes
Wållberg, M., & Cooke, A. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.08.005 · Cited by 155
Antigen-specific immunotherapy of autoimmune and allergic diseases
Sabatos-Peyton, C. A., Verhagen, J., & Wraith, D. C. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.08.006 · Cited by 132
Immune modulation in humans: implications for type 1 diabetes mellitus
Roep, B. O., & Tree, T. I. M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.2 · Cited by 131
Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine
Roep, B. O., Wheeler, D. C. S., & Peakman, M. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30109-8 · Cited by 124
Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment
Kordonouri, O., Pańkowska, E., Rami-Merhar, B. M., Kapellen, T. M., Coutant, R., Hartmann, R., Lange, K., Knip, M., & Danne, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1878-6 · Cited by 124
Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy
Orban, T., Farkas, K., Jalahej, H., Kis, J. T., Treszl, A., Falk, B. A., Reijonen, H., Wolfsdorf, J. I., Ricker, A. T., Matthews, J. B., et al. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.10.005 · Cited by 128
Insect cell technology is a versatile and robust vaccine manufacturing platform
Mena, J. A., & Kamen, A. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.24 · Cited by 124
No Effect of the Altered Peptide Ligand NBI-6024 on β-Cell Residual Function and Insulin Needs in New-Onset Type 1 Diabetes
Walter, M., Philotheou, A., Bonnici, F., Ziegler, A.-G., Jimenez, R., & on behalf of the NBI-6024 Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0449 · Cited by 119
Type 1 diabetes: A predictable disease
Simmons, K. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i3.380 · Cited by 129
Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN–JDRF Type 1 Diabetes Combination Therapy Assessment Group
Matthews, J. B., Staeva, T. P., Bernstein, P., Peakman, M., & von Herrath, M. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04153.x · Cited by 118
Type 1 Diabetes: Current Concepts in Epidemiology, Pathophysiology, Clinical Care, and Research
Gan, M. J., Albanese-O’Neill, A., & Haller, M. J. (2012) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2012.07.002 · Cited by 125
Immune therapy in type 1 diabetes mellitus
Lernmark, Å., & Larsson, H. E. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.237 · Cited by 109
Stopping Type 1 Diabetes: Attempts to Prevent or Cure Type 1 Diabetes in Man
Skyler, J. S., & Ricordi, C. (2010) · Diabetes · doi:10.2337/db10-1114 · Cited by 109
Banting Lecture 2009: An Unfinished Journey: Molecular Pathogenesis to Prevention of Type 1A Diabetes
Eisenbarth, G. S. (2010) · Diabetes · doi:10.2337/db09-1855 · Cited by 107
Immune therapy for type 1 diabetes mellitus—what is unique about anti-CD3 antibodies?
Chatenoud, L. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.275 · Cited by 105
GABAergic system in the endocrine pancreas: a new target for diabetes treatment
Wang, Q., Prud'homme, G., & Wan, Y. (2015) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s50642 · Cited by 100
Antigen-Specific Immunotherapy for Type 1 Diabetes: Maximizing the Potential
Peakman, M., & von Herrath, M. (2010) · Diabetes · doi:10.2337/db10-0630 · Cited by 98
Analysis of Covariance in Randomized Trials: More Precision and Valid Confidence Intervals, Without Model Assumptions
Wang, B., Ogburn, E. L., & Rosenblum, M. (2019) · Biometrics · doi:10.1111/biom.13062 · Cited by 95
Lessons From the Mixed-Meal Tolerance Test
Besser, R. E. J., Shields, B. M., Casas, R., Hattersley, A. T., & Ludvigsson, J. (2013) · Diabetes Care · doi:10.2337/dc12-0836 · Cited by 91
Self-citation
Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes
Waldron-Lynch, F., & Herold, K. C. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3402 · Cited by 96
CXCR1/2 Inhibition Blocks and Reverses Type 1 Diabetes in Mice
Citro, A., Valle, A., Cantarelli, E., Mercalli, A., Pellegrini, S., Liberati, D., Daffonchio, L., Kastsiuchenka, O., Ruffini, P. A., Battaglia, M., et al. (2014) · Diabetes · doi:10.2337/db14-0443 · Cited by 90
Psychological Stress in Children May Alter the Immune Response
Carlsson, E., Frostell, A. S., Ludvigsson, J., & Faresjö, M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301713 · Cited by 92
Self-citation
Immune Tolerance for Autoimmune Disease and Cell Transplantation
Luo, X., Miller, S. D., & Shea, L. D. (2016) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110315-020137 · Cited by 91
The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation
Bayer, A. L., Pugliese, A., & Malek, T. R. (2013) · Immunologic Research · doi:10.1007/s12026-013-8452-5 · Cited by 89
ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset
Vaziri‐Sani, F., Oak, S. A., Radtke, J. R., Lernmark, Å., Lynch, K. F., Agardh, C. D., Cilio, C., Lethagen, Å., Örtqvist, E., Landin‐Olsson, M., et al. (2010) · Autoimmunity · doi:10.3109/08916930903555927 · Cited by 87
Self-citation
Autologous Umbilical Cord Blood Transfusion in Very Young Children With Type 1 Diabetes
Haller, M. J., Wasserfall, C. H., MCGRAIL, K. M., Cintrón, M., Brusko, T. M., Wingard, J. R., Kelly, S. S., Shuster, J. J., Atkinson, M. A., & Schatz, D. (2009) · Diabetes Care · doi:10.2337/dc09-0967 · Cited by 87
Diabetogenic T lymphocytes in human Type 1 diabetes
Roep, B. O., & Peakman, M. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.10.001 · Cited by 98
Prevention and Reversal of Type 1 Diabetes—Past Challenges and Future Opportunities
Skyler, J. S. (2015) · Diabetes Care · doi:10.2337/dc15-0349 · Cited by 92
Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial
Zhao, Y. L., Jiang, Z., Zhao, T., Ye, M., Hu, C., Zhou, H., Yin, Z., Chen, Y., Zhang, Y., Wang, S., et al. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-160 · Cited by 84
The Long and Winding Road to Understanding and Conquering Type 1 Diabetes
Santamaría, P. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.003 · Cited by 87
Breakdown in Peripheral Tolerance in Type 1 Diabetes in Mice and HumansPreprint
Jeker, L. T., Bour-Jordan, H., & Bluestone, J. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007807 · Cited by 82
Vaccine against autoimmune disease: antigen-specific immunotherapy
Anderson, R. P., & Jabrì, B. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.02.004 · Cited by 81
Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial
Ludvigsson, J., Hjorth, M., Chéramy, M., Axelsson, S., Pihl, M., Forsander, G., Nilsson, N.-O., Samuelsson, B.-O., Wood, T., Åman, J., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1988-1 · Cited by 79
Self-citation
Immunotherapy for the Prevention and Treatment of Type 1 Diabetes
Rewers, M., & Gottlieb, P. A. (2009) · Diabetes Care · doi:10.2337/dc09-0374 · Cited by 80
Central Nervous System Destruction Mediated by Glutamic Acid Decarboxylase-Specific CD4+ T Cells
Burton, A. R., Baquet, Z. C., Eisenbarth, G. S., Tisch, R., Smeyne, R. J., Workman, C. J., & Vignali, D. A. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903728 · Cited by 79
Phases of type 1 diabetes in children and adolescents
Couper, J., Haller, M. J., Ziegler, A., Knip, M., Ludvigsson, J., & Craig, M. E. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12188 · Cited by 81
Self-citation
Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents
Ludvigsson, J., Carlsson, A., Deli, A., Forsander, G., Ivarsson, S. A., Kockum, I. S., Lindblad, B., Marcus, C., Lernmark, Å., & Samuelsson, U. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.03.003 · Cited by 75
Self-citation
T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives
Mallone, R., Brezar, V., & Boîtard, C. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/513210 · Cited by 81
Prediction and prevention of Type 1 diabetes mellitus
Zhang, L., & Eisenbarth, G. S. (2010) · Journal of Diabetes · doi:10.1111/j.1753-0407.2010.00102.x · Cited by 74
Progress in immune-based therapies for type 1 diabetes
von Herrath, M., Peakman, M., & Roep, B. O. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12085 · Cited by 76
Kinetics of the Post-Onset Decline in Zinc Transporter 8 Autoantibodies in Type 1 Diabetic Human Subjects
Wenzlau, J. M., Walter, M., Gardner, T. J., Frisch, L. M., Yu, L., Eisenbarth, G. S., Ziegler, A., Davidson, H. W., & Hutton, J. C. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0169 · Cited by 75
GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients
Hjorth, M., Axelsson, S., Rydén, A., Faresjö, M., Ludvigsson, J., & Casas, R. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.10.004 · Cited by 73
Self-citation
Progressive Erosion of β-Cell Function Precedes the Onset of Hyperglycemia in the NOD Mouse Model of Type 1 Diabetes
Ize-Ludlow, D., Lightfoot, Y. L., Parker, M., Xue, S., Wasserfall, C. H., Haller, M. J., Schatz, D., Becker, D. J., Atkinson, M. A., & Mathews, C. E. (2011) · Diabetes · doi:10.2337/db11-0373 · Cited by 72
Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP)
Dungan, K. M., Buse, J. B., & Ratner, R. E. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.999 · Cited by 69
The rise, fall, and resurgence of immunotherapy in type 1 diabetes
Nasr, M. B., D’Addio, F., Usuelli, V., Tezza, S., Abdi, R., & Fiorina, P. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.07.004 · Cited by 68
Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes
Hannelius, U., Beam, C. A., & Ludvigsson, J. (2020) · Diabetologia · doi:10.1007/s00125-020-05227-z · Cited by 68
Self-citation
Management of diabetes mellitus in infants
Karges, B., Meißner, T., Icks, A., Kapellen, T. M., & Holl, R. W. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.204 · Cited by 69
Insulin B chain 9–23 gene transfer to hepatocytes protects from type 1 diabetes by inducing Ag-specific FoxP3 + T regs
Akbarpour, M., Goudy, K., Cantore, A., Russo, F., Sanvito, F., Naldini, L., Annoni, A., & Roncarolo, M. G. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3032 · Cited by 72
Serological autoantibody profiling of type 1 diabetes by protein arrays
Miersch, S., Bian, X., Wallstrom, G. L., Sibani, S., Logvinenko, T., Wasserfall, C. H., Schatz, D., Atkinson, M. A., Qiu, J., & LaBaer, J. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2013.10.018 · Cited by 64
Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes
Roep, B. O., & Peakman, M. (2010) · Nature reviews. Immunology · doi:10.1038/nri2705 · Cited by 63
Safety and efficacy of autoantigen‐specific therapy with 2 doses of alum‐formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial
Larsson, H. E., Lundgren, M., Jónsdóttir, B., Cuthbertson, D. D., Krischer, J. P., & for the DiAPREV‐IT Study Group (2017) · Pediatric Diabetes · doi:10.1111/pedi.12611 · Cited by 63
European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 – Part 2
Knobler, R., Arenberger, P., Arun, A., Assaf, C., Bagot, M., Berlin, G., Bohbot, A., Calzavara‐Pinton, P., Child, F. J., Cho, A., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16889 · Cited by 63
Self-citation
Molecular Targeting of Islet Autoantigens
Stadinski, B. D., Kappler, J. W., & Eisenbarth, G. S. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.008 · Cited by 63
Advances in our understanding of the pathophysiology of Type 1 diabetes: lessons from the NOD mouse
Jayasimhan, A., Mansour, K. P., & Slattery, R. M. (2013) · Clinical Science · doi:10.1042/cs20120627 · Cited by 63
Textbook of Diabetes
Delli, A. J., Larsson, H. E., Ivarsson, S. A., & Lernmark, Å. (2010) · Wiley eBooks · doi:10.1002/9781444324808 · Cited by 69
Self-citation
Anti-CD3 antibodies for type 1 diabetes: beyond expectations
Bach, J.-F. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60980-x · Cited by 59
Introduction to ISPAD Clinical Practice Consensus Guidelines 2014 Compendium
Acerini, C. L., Craig, M. E., de Beaufort, C. E., Maahs, D. M., & Hanås, R. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12182 · Cited by 59
Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial
Krogvold, L., Mynarek, I. M., Ponzi, E., Mørk, F. B., Hessel, T. W., Roald, T., Lindblom, N., Westman, J., Barker, P., Hyöty, H., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02576-1 · Cited by 55
Self-citation
Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes
Tatović, D., McAteer, M. A., Barry, J., Barrientos, Á. G., Terradillos, K. R., Perera, I., Kochba, E., Levin, Y., Dul, M., Coulman, S. A., et al. (2022) · Immunotherapy Advances · doi:10.1093/immadv/ltac002 · Cited by 60
Self-citation
Hypomethylation within gene promoter regions and type 1 diabetes in discordant monozygotic twins
Elboudwarej, E., Cole, M. B., Briggs, F. B. S., Fouts, A., Fain, P. R., Quach, H., Quach, D. L., Sinclair, E., Criswell, L. A., Lane, J. A., et al. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.12.003 · Cited by 57
Acute Versus Progressive Onset of Diabetes in NOD Mice: Potential Implications for Therapeutic Interventions in Type 1 Diabetes
Mathews, C. E., Xue, S., Posgai, A. L., Lightfoot, Y. L., Li, X., Lin, A., Wasserfall, C. H., Haller, M. J., Schatz, D., & Atkinson, M. A. (2015) · Diabetes · doi:10.2337/db15-0449 · Cited by 57
Current approaches to measuring human islet-antigen specific T cell function in type 1 diabetes
Mannering, S. I., Wong, F. S., Durinovic‐Belló, I., Brooks‐Worrell, B., Tree, T. I. M., Cilio, C., Schloot, N. C., & Mallone, R. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04237.x · Cited by 56

Authors: Ludvigsson, J., Faresjö, M., Hjorth, M., Axelsson, S., Chéramy, M., Pihl, M., Vaarala, O., Forsander, G., Ivarsson, S., Johansson, C., Lindh, A., Nilsson, N.-Ö., Åman, J., Örtqvist, E., Zerhouni, P., & Casas, R.
Affiliations: Linköping University (SE)
ORCID: Ludvigsson, Johnny
Faresjö, Maria
Hjorth, Maria
Forsander, Gun
Örtqvist, Eva
Casas, Rosaura
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2008-10-30
Volume: 359
Issue: 18
Pages: 1909-1920
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa0804328
OpenAlex: W2041637201
Cited by: 520
References: 32
Citations by year: 2026: 10 · 2025: 13 · 2024: 13 · 2023: 13 · 2022: 15 · 2021: 16 · 2020: 21 · 2019: 10 · 2018: 14 · 2017: 12 · 2016: 26 · 2015: 20 · 2014: 28 · 2013: 55 · 2012: 51
FWCI: 38.35
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Lund University Publications (Lund University) (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords: type 1 diabetes, glutamic acid decarboxylase, glutamic acid decarboxylase antibodies, residual insulin secretion, C-peptide, recent-onset diabetes, autoimmunity, mixed meal tolerance test
MeSH terms: Insulin Secretion, Adolescent, Analysis of Variance, Autoantibodies, C-Peptide, Child, Diabetes Mellitus, Type 1, Female, Glutamate Decarboxylase, Humans, Hypoglycemic Agents, Immunotherapy, Injections, Subcutaneous, Insulin, Male

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks